GlassScriptPhysician profile
Alex Drohan
NPI 1437732393
$5,464.15
in general payments reported to CMS, 2019-2025
20 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $648 · 2023: $1,100 · 2024: $2,134 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,281 · Education: $310 · Consulting Fee: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,281.14 |
| Education | $309.98 |
| Consulting Fee | $124.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $737.40 | 2022-2025 | |
| Galderma Laboratories, L.P. | $697.31 | 2023-2025 | Epsolay, Oracea, Nemluvio |
| Ucb, INC. | $613.33 | 2022-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $609.89 | 2023-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $377.59 | 2023-2025 | Ilumya |
| Janssen Biotech, INC. | $369.41 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $324.70 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $315.34 | 2023-2025 | Zoryve |
| Biofrontera INC. | $249.04 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Novartis Pharmaceuticals Corporation | $239.95 | 2024-2025 | |
| Incyte Corporation | $204.20 | 2021-2025 | Opzelura |
| Pfizer INC. | $188.94 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.71 | 2023-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $110.76 | 2024 | Cabtreo, Duobrii, Jublia |
| Lilly USA, LLC | $104.38 | 2024-2025 | Ebglyss, Taltz, Olumiant |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $69.83 | 2025 | Libtayo, Dupixent |
| Amgen INC. | $48.59 | 2025 | Otezla |
| Leo Pharma INC. | $23.10 | 2025 | Anzupgo |
| Verrica Pharmaceuticals INC. | $21.86 | 2023 | Ycanth |
| Organon LLC | $16.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Drohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.